Protease-Activated Receptor 2-Mediated β-Arrestin-Epidermal Growth Factor Receptor-ERK Signaling Axis Was Critical for Overcoming Gefitinib Resistance in Non-Small Cell Lung Cancer Cells. Here, EGFR is linked to non-small cell lung carcinoma.